Carisoprodol

Concomitant opioid use increases overdose risk by 84% (adjusted HR 1.84, 95% CI 1.34-2.54). The 'Holy Trinity' combination (carisoprodol + opioid + benzodiazepine) carries the highest mortality risk. Benefit-risk ratio does not support co-prescription.

The combination produces additive respiratory depression through convergent GABA-A receptor mechanisms. The 'Holy Trinity' pattern (carisoprodol + benzodiazepine + opioid) is associated with the highest overdose mortality.

Patients with pre-existing respiratory compromise (COPD, sleep apnea, neuromuscular disorders affecting respiration) face reduced safety margin due to carisoprodol's dose-dependent respiratory depression via direct GABA-A channel gating.

The pronounced muscle relaxation produced by carisoprodol's GABA-A activity may exacerbate weakness in myasthenia gravis, potentially compromising respiratory muscle function.

SSRIs, SNRIs, MAOIs, tramadol, and triptans should be used with caution. Case series (Bramness et al. 2005) and a 2025 case report document serotonin syndrome with carisoprodol. The mechanism is entirely uncharacterized — this is a safety-critical pharmacological gap.

Severe hepatic impairment may alter the balance between carisoprodol and meprobamate exposure and reduce overall clearance, increasing CNS depression risk.

CYP2C19 poor metabolizers (3-5% Caucasian/African, 15-20% Asian populations) experience approximately four-fold higher carisoprodol plasma concentrations at standard therapeutic doses. Fatal outcomes have been documented at routine prescriptions in PM individuals. Alternative muscle relaxants without CYP2C19-dependent metabolism should be used.

Co-administration with CYP2C19 inhibitors increases carisoprodol exposure by reducing conversion to meprobamate, effectively producing the poor metabolizer phenocopy in extensive metabolizers. FDA advises caution and dose adjustment consideration.

History of hypersensitivity to either carisoprodol or its active metabolite meprobamate constitutes an absolute contraindication due to metabolic interconversion.

Despite decades of clinical use, no formal reproductive safety studies have been conducted. FDA labeling notes absence of identified major birth defect risk but acknowledges the evidence gap.

Carisoprodol appears on the American Geriatrics Society Beers Criteria as potentially inappropriate for older adults due to CNS adverse effects and fall risk.

FDA labeling states that safety and efficacy have not been established for patients under 16 years of age.

Alcohol compounds carisoprodol's GABAergic effects, increasing risk of fatal respiratory depression. Alcohol is commonly detected in fatal carisoprodol cases.

FDA labeling explicitly recommends against use exceeding 2-3 weeks. Dependence risk increases substantially with prolonged use; Norwegian data showed 15% of patients developing high-use patterns consistent with dependence.